Korro Bio's Groundbreaking Presentations on RNA Editing
Recently, Korro Bio, Inc. made an exciting announcement regarding its participation at a key industry event, the 20th Annual Meeting of the Oligonucleotide Therapeutics Society. This meeting marks a significant platform for researchers and biopharmaceutical companies dedicated to advancing therapeutic applications of oligonucleotides.
Highlights of the Annual Meeting
The meeting, scheduled to take place from October 6 to 9, will feature Korro Bio's innovative research through one oral and two poster presentations. Korro is known for its commitment to developing genetic medicines that leverage the precision of RNA editing technology. This year, the meeting serves as an opportunity for the company to showcase its latest advancements and connect with experts in the field.
Focus on KRRO-110
Venkat Krishnamurthy, Ph.D., who holds the position of Senior Vice President and Head of Platform at Korro, will deliver a notable oral presentation on KRRO-110. This is the company's first candidate aimed at treating alpha-1 antitrypsin deficiency (AATD), a significant genetic disorder resulting from specific mutations in the SERPINA1 gene. The prospect of addressing such a serious condition through innovative RNA editing is particularly impressive.
Key Presentation Details
The details surrounding Dr. Krishnamurthy's oral presentation are as follows:
- Title: KRRO-110, an RNA Editing Oligonucleotide For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)
- Date: Monday
- Time: 3:20 p.m. ET
Poster Presentations: In-Depth Analysis
In addition to the oral presentation, Korro will feature two poster presentations that delve deeper into the mechanisms and methodologies of RNA editing. These presentations are crafted to highlight Korro's cutting-edge research, showing the potential impacts of their findings on real-world applications.
First Poster Presentation
The first poster presentation, led by Agya Karki, Ph.D., focuses on the purification of human ADAR, illuminating how it enables assessment of oligo-directed RNA editing in a controlled environment. This work aims to predict the in vivo activity of the therapeutic approach.
Second Poster Presentation
The second poster, presented by Zhiji Ren, Ph.D., investigates the on-target and off-target effects of RNA editing oligonucleotides using ADAR1 chimeric enhanced cross-linking immunoprecipitation (eCLIP). This research is crucial for understanding the safety and efficacy of the editing technologies.
About Korro Bio
Korro Bio is driven by a mission to harness the power of RNA editing to create new genetic medicines that can address both rare and common diseases. Unlike traditional approaches that modify DNA, Korro’s platform edits RNA. This key difference allows for precise, temporary changes that can be more controllable and possibly better tolerated by patients in the long term. By focusing on oligonucleotide-based therapies, Korro aims to provide transformative solutions for patients through innovative delivery strategies and a robust adherence to regulatory guidelines.
Connecting with Korro Bio
To learn more about Korro Bio and its pioneering work in genetic medicine, the company can be reached at the following contact points:
Investors: IR@korrobio.com
Media Contact:
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
Frequently Asked Questions
What is the focus of Korro Bio?
Korro Bio specializes in developing RNA editing technologies to create genetic medicines for various diseases.
When is Korro Bio's presentation scheduled?
The oral presentation will take place on Monday at 3:20 p.m. ET.
Who is the speaker for the oral presentation?
Venkat Krishnamurthy, Ph.D., will present on KRRO-110, focusing on AATD.
What are the topics of the poster presentations?
The poster presentations cover the purification of human ADAR and the effects of RNA editing oligonucleotides.
Where can I find more information about Korro Bio?
For additional details about Korro Bio's innovative work, visit their official website at korrobio.com.
